Cargando…
Unveiling the antitumor potential of novel N-(substituted-phenyl)-8-methoxycoumarin-3-carboxamides as dual inhibitors of VEGFR2 kinase and cytochrome P450 for targeted treatment of hepatocellular carcinoma
Being the sixth most diagnosed cancer and the fourth leading cause of cancer-related deaths worldwide, liver cancer is considered as a serious disease with a high prevalence and poor prognosis. Current anticancer drugs for liver cancer have drawbacks, such as limited efficacy in later stages of the...
Autores principales: | Radwan, Eman M., Abo-Elabass, Eman, Abd El-Baky, Atef E., Alshwyeh, Hussah Abdullah, Almaimani, Riyad A., Almaimani, Ghassan, Ibrahim, Ibrahim Abdel Aziz, Albogami, Abdulaziz, Jaremko, Mariusz, Alshawwa, Samar Z., Saied, Essa M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436493/ https://www.ncbi.nlm.nih.gov/pubmed/37601910 http://dx.doi.org/10.3389/fchem.2023.1231030 |
Ejemplares similares
-
Novel 8-Methoxycoumarin-3-Carboxamides with potent anticancer activity against liver cancer via targeting caspase-3/7 and β-tubulin polymerization
por: Alzamami, Ahmad, et al.
Publicado: (2023) -
Novel 2-substituted-quinoxaline analogs with potential antiproliferative activity against breast cancer: insights into cell cycle arrest, topoisomerase II, and EGFR activity
por: Salem, Manar G., et al.
Publicado: (2023) -
Unveiling the interplay between NSAID-induced dysbiosis and autoimmune liver disease in children: insights into the hidden gateway to autism spectrum disorders. Evidence from ex vivo, in vivo, and clinical studies
por: Mohamed, Doaa I., et al.
Publicado: (2023) -
Solanum Procumbens-Derived Zinc Oxide Nanoparticles Suppress Lung Cancer In Vitro through Elevation of ROS
por: Ibrahim Abdel Aziz, Ibrahim, et al.
Publicado: (2022) -
Asymptomatic Bacteriuria in Post Renal Transplant Patients: To Treat or Not?
por: Almaimani, Anas O
Publicado: (2021)